ArticleHelicobacter2017
Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children.
Article in Helicobacter, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06143124 (Bismuth Quadruple Therapy Versus Standard Triple Therapy for the First-line Treatment of Helicobacter Pylori Infection in Children), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bismuth Quadruple Therapy Versus Standard Triple Therapy for the First-line Treatment of Helicobacter Pylori Infection in Children: Efficacy and Safety
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Trial
- Synonymous codon-optimized multiplex qPCR for simultaneous detection ofJournal of clinical microbiology · 2026Article
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- Antibiotic-Resistant Strains of Helicobacter pylori in 50 Antibiotic Treatment-Naive Children in Northeast Poland Diagnosed by Gastric or Duodenal Biopsy Between February 2019 and May 2022.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Current Worldwide Trends in PediatricChildren (Basel, Switzerland) · 2023Review
- Article
- Antibiotic Resistance ofHealthcare (Basel, Switzerland) · 2022Article
- A Culture-Based Strategy Is More Cost Effective Than an Empiric Therapy Strategy in Managing PediatricFrontiers in pediatrics · 2022Article
- Efficacy of Phenotype-vs. Genotype-Guided Therapy Based on Clarithromycin Resistance forFrontiers in pediatrics · 2022Article
- Phenotypic and Genotypic Analysis of ResistantDiagnostics (Basel, Switzerland) · 2020Article
- Genotype profiles ofTherapeutic advances in gastroenterology · 2020Article
- Review
- The Concept of an Ideal Antibiotic: Implications for Drug Design.Molecules (Basel, Switzerland) · 2019Review
- Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children.Helicobacter · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary Helicobacter pylori (H. pylori) infection occurs predominantly in childhood. Antimicrobial resistance is the leading cause for H. pylori eradication failure. The aims of this study were (i) to establish for the first time the antimicrobial resistance of H. pylori strains in infected Slovenian children not previously treated for H. pylori infection and (ii) to evaluate the effectiveness of tailored triple therapy, assuming that eradication rate with tailored triple therapy will be >90%.
methodsData on all treatment-naive children 1-18 years old and treated for H. pylori infection according to susceptibility testing were retrospectively analyzed. All relevant clinical information and demographical information were retrospectively collected from the hospital information systems and/or patients' medical documentation.
resultsThe inclusion criteria were met by 107 children (64.5% girls) with a median age of 12.0 years (range 2.0-17.6 years). Primary antimicrobial resistance rates of H. pylori were 1.0% to amoxicillin (AMO), 23.4% to clarithromycin (CLA), 20.2% to metronidazole (MET), 2.8% to levofloxacin (LEV), and 0.0% to tetracycline (TET). Dual resistances were detected to CLA and MET in 11.5% (n=12) of strains, to CLA and LEV in 2.8% (n=3), and to MET and LEV in 2.9% (n=3). Results of treatment success were available for 71 patients (66.2% girls). Eradication of H. pylori was evaluated using the 13C-urea breath test, monoclonal stool antigen test or in some cases with repeated upper GI endoscopy with histology and cultivation/molecular tests. Eradication was achieved in 61 of 71 (85.9%) patients.
conclusionsThe primary resistance rates of H. pylori to CLA and MET in Slovenia are high. Our data strongly support the fact that in countries with high prevalence of resistant H. pylori strains susceptibility testing and tailored therapy is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.